Overview
TandemAI has secured a $22 million Series A extension to enhance its AI-driven drug discovery platform, addressing challenges in pharmaceutical development. This funding, which raises its total capital to over $80 million since its founding in October 2021, includes contributions from both new and existing investors.
Products
Loading...
Recent Deals
TandemAI has secured a $22 million Series A extension to enhance its AI-driven drug discovery platform, addressing challenges in pharmaceutical development. This funding, which raises its total capital to over $80 million since its founding in October 2021, includes contributions from both new and existing investors.